-
Recent Posts
- Two Leading Spinal Cord Injury Experts Join ReNetX Scientific Advisory Board
- Get registered for Working 2 Walk 2017 today!
- Airline lobby wins another big delay on reporting data for wheelchair damages and losses *January 2019*
- An injectable hydrogel enhances tissue repair after spinal cord injury by promoting extracellular matrix remodeling
- 17th International Symposium on Neural Regeneration
- Combinatory repair strategy to promote axon regeneration and functional recovery after chronic spinal cord injury
- Gait Rehabilitation with a Neurologically Controlled Exoskeleton
- Nanoparticles limit damage in spinal cord injury
- It’s Not a Rat’s Race for Human Stem Cells Grafted to Repair Spinal Cord Injuries
- It’s On! U2FP Working 2 Walk 2017 and SCI Curecast Episode 11
- InVivo Therapeutics restructures and suspends chronic SCI stem cell and gene therapy research programs
- Pretreatment May Unlock the Regenerative Potential of Neural Stem Cells in Chronic Spinal Cord Injury
- Regulateable Chondroitinase ABC gene therapy as a treatment for spinal cord injury
- Miracle chemical ‘cocktail’ could cure spinal cord damage
- Combined expression of pro-regenerative transcription factors and transplanted stem cells to promote corticospinal tract regeneration.
Working 2 Walk 2016
Follow on Twitter
My TweetsSpinal Cord Injury Research and Science at Facebook
Archives
Tag Archives: Jan-Eric Ahlfors
Breakthrough Regenerative Therapeutics Company Establishes Scientific Advisory Board
Montreal, Canada, May 4, 2017 (Newswire.com) – Fortuna Fix Inc. (“Fortuna”), a private, clinical-stage biotech company, is aiming to be the first to eliminate the need for embryonic and fetal stem cells by using direct reprogramming of autologous cells to treat … Continue reading
Posted in Biomaterials, Chronic Spinal Cord Injury Research, Regenerative Medicine, Rehabilitation, Spinal Research, Stem Cell Research, Unite 2 Fight Paralysis
Tagged Jan-Eric Ahlfors, MPH; and Professor James Giordano, PhD; Col. (R) Dallas Hack, PhD; Father Kevin FitzGerald, Professor Michael Fehlings
2 Comments
New World Laboratories pushes forward with clinical trial
New World Laboratories acts as its own research center, allowing it to create its own therapeutic platforms. The company focuses its efforts on three main sectors—therapeutic drugs, medical devices, and cell therapies. For example, the apoptosis program (programmed cell death) … Continue reading
